Teva's multiple sclerosis stalwart Copaxone gets FDA boxed warning for anaphylaxis risk
22nd January 2025 Uncategorised 0More than 80 cases of treatment-associated anaphylaxis have been reported since 1996, according to the FDA’s safety notice on Wednesday. The warning also applies to generics, including Sandoz’s Glatopa. More: Teva's multiple sclerosis stalwart Copaxone gets FDA boxed warning for
read more

